Thoracic research and practice最新文献

{"title":"In Memoriam Friedrich Krause","authors":"Feyza Erkan","doi":"10.5152/thoracrespract.2024.240101","DOIUrl":"https://doi.org/10.5152/thoracrespract.2024.240101","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140510920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Increasing Costs in Severe Chronic Obstructive Pulmonary Disease Exacerbation: Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Assembly","authors":"A. Baha, N. Köktürk, C. Baysan, Burcu Öztürk, Sümeyye Kodalak Cengiz, Yelda Varol, Aydan Mertoğlu, Ali Kadri Çırak, Onur Turan, N. Dursunoğlu, Nilufer Savurmus, A. Gürgün, F. Elmas, L. Çöplü, Ü. Sertçelik, Reyhan Yıldız, İ. Özmen, Aylin Özgen Alpaydın","doi":"10.5152/thoracrespract.2024.23065","DOIUrl":"https://doi.org/10.5152/thoracrespract.2024.23065","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":"36 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140511409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.5152/ThoracResPract.2024.240103","DOIUrl":"https://doi.org/10.5152/ThoracResPract.2024.240103","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":"25 1","pages":"50"},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor’s Recognition Awards and Acknowledgements","authors":"","doi":"10.5152/thoracrespract.2024.240102","DOIUrl":"https://doi.org/10.5152/thoracrespract.2024.240102","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":"17 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140510517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Memoriam Friedrich Krause.","authors":"Feyza Erkan","doi":"10.5152/ThoracResPract.2024.240101.","DOIUrl":"10.5152/ThoracResPract.2024.240101.","url":null,"abstract":"<p><p>Cite this article as: Erkan F. In memoriam Friedrich Krause. Thorac Res Pract. 2024;25(1):4.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":"25 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Narrative Review of the Clinical Trials in Sleep-Related Breathing Disorders from 2022 to Present.","authors":"Aylin Pıhtılı, Canan Gündüz Gürkan, Mehmet Ali Habeşoğlu, Önder Öztürk, Aylin Özsancak Uğurlu, Mehmet Sezai Taşbakan, Yüksel Peker, On Behalf Of The Turkish Thoracic Society Sleep Related Breathing Disorders Working Group","doi":"10.5152/ThoracResPract.2023.23104","DOIUrl":"10.5152/ThoracResPract.2023.23104","url":null,"abstract":"<p><p>Sleep-related breathing disorders (SRBD) comprise obstructive sleep apnea (OSA), central sleep apnea (CSA), obesity-hypoventilation syndrome (OHS), as well as isolated sleep-related hypoxemia (ISRH), according to the recent International Classification of Sleep Disorders 3. During the last decades, there have been cumulative research reports indicating an association between the SRBD and increased cardiometabolic illness and death, as well as decreased quality of life. Notwithstanding, the results have been inconclusive, and the evidence level was not high regarding the effect of treatment for the SRBD on adverse outcomes. In the current work, we aim to give a comprehensive review of the clinical trials published from January 2022 to August 31, 2023. We highlight the heterogeneity of cardiometabolic disorders among adults with SRBD and particularly emphasize OSA management, drug therapy for OSA, positive airway pressure (PAP) therapy and cardiovascular outcomes, other effects of PAP in pregnancy and neurocognitive function, as well as the effects of surgical treatment and oral appliances. We also underline future directions in OSA management, telemonitoring, and druginduced sleep endoscopy in managing the SRBD, especially OSA. We ascertain that more studies are needed within the CSA, OHS, and ISRH research fields.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"42 - 49"},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138447395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery from Respiratory Failure in Patients with Coronavirus Disease 2019.","authors":"Miraç Öz, Serhat Erol, Aslıhan Gürün Kaya, Özlem Işık, Fatma Çiftci, Güle Çınar, Çağlar Uzun, Alpay Azap, Aydın Çiledağ, Akın Kaya, Özlem Özdemir Kumbasar","doi":"10.5152/ThoracResPract.2023.23001","DOIUrl":"10.5152/ThoracResPract.2023.23001","url":null,"abstract":"<p><strong>Objective: </strong>Coronavirus disease 2019 (COVID-19) can cause hypoxic respiratory failure; long-term oxygen therapy (LTOT) duration is unknown.</p><p><strong>Material and methods: </strong>The aim was to investigate which patients would need LTOT after COVID-19 pneumonia. This single-center, prospective study was conducted at the Ankara University Faculty of Medicine, Department of Chest Diseases, between May 2021 and December 2021. The 70 patients hospitalized for COVID-19 pneumonia and discharged with LTOT due to hypoxemic respiratory failure were included. Patients were divided into 2 groups as group I (LTOT requirement <3 months) and group II (LTOT requirement continued ≥3 months).</p><p><strong>Results: </strong>The mean age was 64.4 ± 13.5 years, and 44 (62.9%) of them were male. The most frequently encountered comorbidities were cardiovascular disease (57.1%) and lung disease (22.9%). While PaO2 levels increased in both groups during the follow-up period, this increment was significantly higher in group I (PaO2: 66.6 ± 9.9 mm Hg, P < .001). The factors affecting the LTOT requirement were evaluated using binary logistic regression. On multivariate analyses of lymphocytes, ferritin, C-reactive protein, PaO2, SaO2, subpleural reticulation, and number of lobes affected (≥3 lobes), the SaO2 level and presence of subpleural reticulation were significantly different between the 2 groups [odds ratio (OR) (95% CI): 0.853 (0.749-0.971), P = .016] and [OR (95% CI): 0.171 (0.042-0.733), P = .017], respectively.</p><p><strong>Conclusion: </strong>A significant proportion of patients who develop respiratory failure due to COVID-19 recover within the first 3 months. Factors determining the LTOT requirement for more than 3 months were SaO2 and the presence of subpleural reticulation.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"26 - 34"},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138447396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Effect of Surgery in Patients with Stage IIIB/N2 Non-small Cell Lung Cancer: A Comparative Study with Definitive Chemoradiotherapy.","authors":"Volkan Erdoğu, Yunus Aksoy, Celal Buğra Sezen, Mustafa Vedat Doğru, Nisa Yıldız, Levent Cansever, Muzaffer Metin","doi":"10.5152/ThoracResPract.2023.23084","DOIUrl":"10.5152/ThoracResPract.2023.23084","url":null,"abstract":"<p><strong>Objective: </strong>We compared the survival outcomes of surgery within multimodality treatment regimens with the outcomes of definitive chemoradiation treatments in patients diagnosed with clinical (c) IIIB/N2 non-small cell lung cancer (NSCLC). We investigated whether surgery within multimodality treatment provides a survival advantage at this stage.</p><p><strong>Material and methods: </strong>Data from 79 patients with cIIIB/N2 between 2009 and 2016 were analyzed retrospectively. While the surgery was performed after neoadjuvant therapy in 51 cases (IIIB/Surgery Group), definitive chemotherapy ± radiotherapy was applied in 28 cases (IIIB/Definitive Group).</p><p><strong>Results: </strong>In cIIIB/N2 cases, the 5-year overall survival (OS) was 27.4%, with a median OS of 24.6 months. The 5-year OS of the IIIB/ Surgery Group was 27.3% (median survival 22.5 months), while it was 28.6% (median survival 29.1 months) in the IIIB/Definitive Group (P = .387, HR = 0.798, 95% CI, 0.485-1.313). Although there was a survival advantage in the group with a pathological complete response (PCR) after surgery (n = 14) compared to the group that did not (n = 37), the observed difference was not statistically significant. (5-year OS; 42.9% vs. 18.5%, P = .104). Additionally, there was no statistically significant difference between the survival of PCR patients and the IIIB/Definitive Group in terms of OS (P = .488).</p><p><strong>Conclusion: </strong>Surgery performed within multimodality treatment regimens in selected cIIIB/N2 cases did not provide a survival advantage over definitive chemoradiation treatments.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"35-41"},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138447397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Patients with COVID-19 Followed Up in Intensive Care Units in the Second Year of the Pandemic: A Multicenter Point Prevalence Study.","authors":"Sinem Güngör, Özlem Ediboğlu, Özlem Yazıcıoğlu Moçin, Nalan Adıgüzel, Eylem Tuncay, İnşa Gül Ekiz İşcanlı, Berrin Er, Zuhal Karakurt, Sema Turan, Behiye Deniz Kosovalı, Nevzat Mehmet Mutlu, Duygu Kayar, Şerife Gökbulut Bektaş, Elmas Uysal, Fatih Seğmen, Gürayalp Alp, Deniz Erdem, Nazan Has Selmi, Pınar Güven, Zerrin Özçelik, Merve Ocakcıoğlu, Canan Yazıcı Özgür, Rabia Yılmaz, Deniz Bilgi Özel, Halil Cebeci, Bahar Güler, Canan Cansever, Mehmet Çakırca, Hansa İnceöz, İlker Solmaz, Fatma Özkan Sipahioğlu, Eda Macit Aydın, Hakan Dayanır, Sait Fatih Öner, Umut Karatepe, Serkan Özen, Maruf Boran, Dursun Fırat Ergül, Umut Sabri Kasapoğlu, Leman Acun Delen, Erol Toy, Koray Altun, Tuna Albayrak, Hülya Yanal, Gizem Zaim, Volkan Yarar, Gökhan Kılınç, Mustafa Deniz, Esra Özdemir, Veysel Garani Soylu, Ayşe Yılmaz, Saba Mukaddes Saygılı, Ejder Kamil Öztürk, Begüm Ergan, Selin Eyüpoğlu, Yiğit Şahin, Beyza Yüksel, Azime Bulut, Aykut Sarıtaş, Hicret Yeniay, Mürşide Genç, Feyza Kargın, Osman Özcan, Ebru Karakoç, Ümran Karaca, Didem Sözütek, Sema Sarı, Nimet Şenoğlu, Hakan Aygün, Arzu Ceren Yiğit, Nilgün Kavruk, Çağdaş Alp Uzan, Murat Bıçakcıoğlu, Serkan Solak, Hatice Kutbay Özçelik, Kamuran Uluç, İlker Yıldırım, Makbule Cavidan Arar, İsmail Demirel, Soner Umut Küver, Eylem Sercan Özgür, Kutlay Aydın, Gül Erdal Dönmez, Gülbin Aygencel, Aliye Esmaoğlu, Berrak Sebil Aydın, Murat Emre Tokur, Pervin Korkmaz Ekren, Yusuf Aydemir, Başak Çakır Güney, Ömer Yavuz Erdil, Abdurrahman Tünay, Türkan Bahadır, Serkan Uçkun, Nazan Kocaoğlu, Hüseyin Ulaş Pınar, Nurcan Kutluer Karaca, Hamza Gültekin, Pınar Ayvat, Ayşe Belin Özer, Ahmet Eroğlu, Ufuk Kuyrukluyıldız, Çağdaş Baytar, Hilal Ayoğlu, Serpil Mızrakçı, Hatice Metin, Özgecan Pırıl Zanbak Mutlu, Hakan Yılmaz, Filiz Tüzüner","doi":"10.5152/ThoracResPract.2023.23024","DOIUrl":"10.5152/ThoracResPract.2023.23024","url":null,"abstract":"<p><strong>Objective: </strong>A 1-day point prevalence study was planned to obtain country data by determining the clinical characteristics, follow-up and treatment methods of coronavirus disease 2019 (COVID-19) cases that required intensive care unit (ICU) treatment in the second year of the pandemic.</p><p><strong>Material and methods: </strong>All patients who were hospitalized in the ICUs due to COVID-19 between March 11, 2022, 08.00 am, and March 12, 2022, 08.00 am, were included in the study. Demographic characteristics, intensive care and laboratory data, radiological characteristics, and follow-up results of the patients were recorded.</p><p><strong>Results: </strong>A total of 811 patients from 59 centers were included in the study, 59% of the cases were male, and the mean age was 74 ± 14 years. At least one comorbid disease was present in 94% of the cases, and hypertension was the most common. When ICU weight scores were examined, Acute Physiology and Chronic Health Evaluation-II: 19 (15-27) and Sequential Organ Failure Assessment: 7 (4-10) were seen. Sepsis was present in 37% (n = 298) of cases. PaO2/FiO2 ratios of the patients were 190 the highest and 150 the lowest and 51% of the cases were followed via invasive mechanical ventilation. On the study day, 73% bilateral involvement was seen on chest x-ray, and ground-glass opacities (52%) were the most common on chest tomography. There was growth in culture in 40% (n = 318) of the cases, and the most common growth was in the tracheal aspirate (42%).</p><p><strong>Conclusion: </strong>The clinical course of COVID-19 is variable, and ICU follow-up was required due to advanced age, comorbidity, presence of respiratory symptoms, and widespread radiological involvement. The need for respiratory support and the presence of secondary infection are important issues to be considered in the follow-up. Despite the end of the second year of the pandemic and vaccination, the high severity of the disease as well as the need for follow-up in ICUs has shown that COVID-19 is an important health problem.COVID-19, intensive care, intensive care unit, pandemic, follow-up</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"11 - 16"},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138296770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the Optimal Treatment Regimen of Low-MolecularWeight Heparin in Coronavirus Disease 2019 Pneumonia?","authors":"Ömer Selim Unat, Ziya Karimov, Damla Serçe Unat, Gizem Damar, Pakize Çağlayan, Faik Teymurlu, Mehmet Sezai Taşbakan, Pervin Korkmaz Ekren, Özen K. Başoğlu, Abdullah Sayıner","doi":"10.5152/ThoracResPract.2023.23039","DOIUrl":"10.5152/ThoracResPract.2023.23039","url":null,"abstract":"<p><strong>Objective: </strong>The optimal anticoagulant treatment regimen in hospitalized coronavirus disease 2019 (COVID-19) patients is uncertain. This study aimed to compare the rates of disease progression and mortality in patients treated with low-molecular-weight heparin (LMWH) according to baseline d-dimer levels and in those who received a fixed-dose regimen irrespective of the d-dimer level.</p><p><strong>Material and methods: </strong>This was a retrospective analysis of all patients admitted to a university hospital for COVID-19 pneumonia during a 1-year period. The protocol for d-dimer-driven therapy (on-protocol) was as follows: prophylactic dose when the baseline level is <1000 ng/mL, intermediate dose when the level is between 1000 and 3000 ng/mL, and therapeutic dose when the level is >3000 ng/mL. We compared the progression and mortality rates between the on-protocol and off-protocol treatment groups. The offprotocol group consisted of patients that received a fixed-dose LMWH regimen, which was not in accordance with the defined protocol.</p><p><strong>Results: </strong>Of 384 patients (mean age 61.5 ± 15.9 years, 216 male), 294 patients with complete data composed the study group, and 174 patients were treated on-protocol and 120 patients were treated off-protocol. The on-protocol group had lower C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), and d-dimer levels and higher SpO2/FiO2 levels at admission. Disease progression developed in 45/174 on-protocol patients (25.9%) vs. 53/120 off-protocol patients (44.2%) during the follow-up (P = .001), and mortality was 29 (16.7%) vs. 32 (26.7%), respectively (P = .041). Logistic regression analysis was performed and included age, presence of comorbidities, LMWH regimen, baseline SpO2/FiO2, CRP, and LDH levels as independent variables. The presence of cardiac comorbidity, age, CRP, and LDH levels, but not the LMWH treatment regimen, were associated with both disease progression and mortality.</p><p><strong>Conclusion: </strong>A d-dimer-driven LMWH treatment protocol is not associated with better clinical outcomes in hospitalized COVID-19 patients.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"5 - 10"},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11158007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134650596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}